JP Jenkins Ltd · ISIN: GB00BDHSP575 · EQS - Company News

Destiny Pharma to Deliver Presentation at the European Society of Clinical Microbiology and Infectious Disease conference on XF-73 Nasal Gel and the Use of Post-Operative Antibiotics in Cardio-vascula

20th Aug 2024 JPJ: DEST ISIN: GB00BDHSP575    Destiny Pharma plc ("Destiny Pharma" or "the Company")     Destiny Pharma to Deliver Presentation at the European Society of Clinical Microbiology and Infectious Disease conference on XF-73 Nasal Gel and the Use of Post-Operative Antibiotics in Cardio-vascular Surgery Patients.     Brighton, United Kingdom – 20 August 2024 – Destiny Pharma, a clinical stage biotechnology company focused on the development and commercialisation of novel me...

LSE:DEST Price indication powered by TradingView

About the publication

Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor

Smart tools for smart investors can be found in our Tools section

Corporate News JP Jenkins Ltd

In this overview you can view company news in the chronological order of publication. The source information comes from EQS News, the leading European news distributor. The most recent news item is listed first.
Back to Corporate News Overview
This might be interesting for you as well
Analyst Ratings (0)
Directors Dealings (0)
Short Selling (DE) (0)
Short Selling (UK) (0)
20 August 2024 12:52PM
Destiny Pharma to Deliver Presentation at the European Society of Clinical Microbiology and Infectious Disease conference on XF-73 Nasal Gel and the Use of Post-Operative Antibiotics in Cardio-vascula
GB00BDHSP575
20th Aug 2024 JPJ: DEST ISIN: GB00BDHSP575    Destiny Pharma plc ("Destiny Pharma" or "the Company")     Destiny Pharma to Deliver Presentation at the European Society of Clinical Microbiology and Infectious Disease conference on XF-73 Nasal Gel and the Use of Post-Operative Antibiotics in Cardio-vascular Surgery Patients.     Brighton,...
JP Jenkins Ltd
About the publication
14 August 2024 12:20PM
Destiny Pharma initiates research to explore XF drug potential for CF
GB00BDHSP575
  13th Aug 2024 JPJ: DEST ISIN: GB00BDHSP575     Destiny Pharma plc("Destiny Pharma" or "the Company") Destiny Pharma initiates research to explore XF drug potential for CF   Study to investigate the potential of XF-73 to treat MRSA infection in people with cystic fibrosis   Brighton, United Kingdom – 14 August 2024 – Destiny Pharma (JP...
JP Jenkins Ltd
About the publication
13 August 2024 10:36AM
Destiny Pharma plc shares now trading on JP Jenkins
GB00BDHSP575
13th Aug 2024 JPJ: DEST ISIN: GB00BDHSP575   Destiny Pharma plc ("Destiny Pharma" or "the Company") Shares now trading on JP Jenkins   London, UK, 13th Aug 2024 - Destiny Pharma plc (JPJ: DEST), a clinical stage biotechnology company focused on the development and commercialisation of novel medicines to prevent and cure life-threatening in...
JP Jenkins Ltd
About the publication
21 November 2022 03:19PM
Destiny Pharma PLC 'leads the world' in new approach to preventing hospital infections
GB00BDHSP575
Contact DetailsProactiveProactive UK Ltd+44 20 7989 0813uk@proactiveinvestors.comNews Source: News Direct 21.11.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
Destiny Pharma PLC
About the publication
21 November 2022 03:19PM
Destiny Pharma PLC 'leads the world' in new approach to preventing hospital infections
GB00BDHSP575
Contact DetailsProactiveProactive UK Ltd+44 20 7989 0813uk@proactiveinvestors.comNews Source: News Direct 21.11.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
Destiny Pharma PLC
About the publication
More JP Jenkins Ltd related information
Type Total Last Made by Go to
Corporate Research 0 - - Corporate Research
Directors Dealings 0 - - DD
Short Seller (DE) 0 - - SSR (DE)
Short Seller (UK) 0 - - SSR (UK)
Disclaimer:

The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster. 
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.

If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.

v.07062023 EN